ADMA Biologics Earns BioNJ 2020 Innovator Award for Primary Immunodeficiency Treatment

According to a story from gurufocus.com, the biopharmaceutical company ADMA Biologics, Inc., has earned the 2020 BioNJ Innovator Award. This award was given as acknowledgement of the company’s successful development of ASCENIV, which is a plasma-derived form of intravenous immunoglobulin (IVIG). The product was approved in April of 2019 as a treatment for primary immunodeficiency in both adolescents aged 12-17 and adults. ADMA is focused on the development of plasma-based therapies for infectious diseases and patients with immune system deficiencies.

About Primary Immunodeficiency

Primary immunodeficiency describes a group of disorders which are characterized by some degree of dysfunction of the immune system. These diseases are generally the result of genetic abnormalities and are not the result of other conditions or external factors. In some cases, they may remain latent until a certain environmental trigger causes problems to appear. The symptoms of these disorders may vary considerably in severity and depend on the specific subtype. However, some symptoms may include chronic, persistent infections, developmental delays due to infection, dysfunction of certain organs, and increased vulnerability to autoimmune disorders or blood cancers such as lymphoma. Treatment of most types of primary immunodeficiency is symptomatic and supportive; patients may be told to take steps to avoid exposure to pathogens; medications to enhance immune function and fight infections are also used. To learn more about primary immunodeficiency, click here.

About ASCENIV

The award is given both to highlight the achievements of the recipients and celebrate the role that New Jersey continues to play in the field of drug development. ASCENIV is indicated for a wide variety of forms of primary immunodeficiency, such as severe combined immunodeficiency, common variable immunodeficiency, X-linked and congenital agammaglobulinemia, and Wiskott-Aldrich syndrome. The therapy should be able have a significant impact on patients affected by this class of serious diseases in the US.

BioNJ is a non-profit organization that is primarily focused on fostering a favorable environment for the biotechnology industry in the state of New Jersey. Learn more about its activities here.

 


Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email